Charge Detection Mass Spectrometry (CDMS)

Charge Detection Mass Spectrometry (CDMS) measures the mass of individual ions directly. The technique captures both the charge and the m/z of each ion, which allows calculation of the true mass for every particle measured. This makes CDMS useful for samples that contain a mixture of empty, partial, full, and abnormal particles, especially in AAV and LNP programs.

CDMS is mainly used as a characterization and orthogonal confirmation tool when standard assays (SEC-MALS, AUC, ddPCR) cannot resolve complex or heterogeneous particle populations.

• AUC is widely regarded as the gold-standard, high-resolution, direct method for AAV empty/partial/full analysis; SEC-MALS is more indirect and lower resolving for capsid content. 
• CDMS is an orthogonal, mass-based single-particle method that’s rapidly gaining adoption . Its ability to perform single-particle mass measurements provides unambiguous, high-resolution data that is often considered more direct and definitive than legacy techniques.
• Looking ahead, improvements in throughput, software, and robustness may make CDMS more practical in routine characterization workflows, but it is not yet a primary QC release method.

CDMS measures two values for each ion:

Charge (z)

Mass-to-charge ratio (m/z)

Because these values are measured independently for the same particle, the instrument can calculate the ion’s true mass. Repeating this for thousands of particles produces a mass distribution that shows the populations present in the sample.

This direct mass approach avoids the need for deconvolution, and other assumptions that limit conventional MS for megadalton-scale species.

The main output is a mass histogram built from thousands of single-particle measurements. Each peak corresponds to a distinct population. For AAV, these peaks usually represent empty, partial, full, and occasionally overfull capsids.

Relative abundance is estimated by comparing the area under each peak. CDMS is especially good at separating species that overlap in SEC-MALS or are difficult to classify by AUC alone.

Charge distributions may also give clues about structural differences or changes in particle organization.

• Direct mass measurement
• High resolution for heterogeneous samples
• Clear separation of empty/partial/full/overfull species
• Detects rare or atypical particle types
• Works across multiple modalities (AAV, LNPs, protein complexes, plasmids)
• Useful as an orthogonal confirmation method

• Throughput is lower than plate-based or optical assays
• Requires clean, well-prepared samples
• Interpretation still requires expertise
• Not yet common as a GMP release method
• Mass alone does not provide potency or sequence information

While still an emerging technique in GMP, validation would focus on ICH Q2(R2) parameters, including:

• Specificity: Demonstrating the ability to resolve and quantify the target species (e.g., full capsids) from other components (empty, partials, aggregates).
• Precision: Assessing repeatability and intermediate precision of the calculated relative abundances of key species.
• Accuracy: Often challenging to establish a true value. Accuracy is typically demonstrated by comparison to an orthogonal method (like AUC) or by analyzing well-characterized in-house reference materials.
• Range: Defining the concentration range over which the method provides precise and accurate results.
• System Suitability: Defining acceptance criteria for key performance indicators, such as the mass accuracy of a known standards to ensure the instrument is performing correctly for each run.

• Standardization is a critical and evolving area. USP AAV8 Empty and Full Capsids Reference Standards are available and used to support method comparison and system suitability; harmonized procedures are still evolving. (One can create ratio mixtures from the USP empties/full). Standardization relies heavily on:
• Instrument Calibration: Using well-characterized protein standards (e.g., GroEL-often used to calibrate the charge-intensity constant in Orbitrap-CDMS workflows) to ensure the mass accuracy of the instrument.
• In-House Reference Materials: Establishing a well-characterized in-house lot of material to serve as a benchmark for comparing results across runs, instruments, and time.

• AAV gene therapy: most common application; resolves capsid content distributions with high clarity
• LNPs: tracks shifts in particle mass distributions across formulations or processing conditions
• Protein complexes: evaluates assembly states and stoichiometry
• Plasmids: can distinguish compact, supercoiled, and partially degraded structures
• VLPs and vaccines: useful for mass and aggregation profiling